Talwin Nx Side Effects
Generic name: naloxone / pentazocine
Note: This document contains side effect information about naloxone / pentazocine. Some of the dosage forms listed on this page may not apply to the brand name Talwin Nx.
Some side effects of Talwin Nx may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to naloxone / pentazocine: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking naloxone / pentazocine: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have a serious side effect such as:
weak or shallow breathing, slow heartbeats;
confusion, hallucinations, unusual thoughts or behavior;
severe weakness or dizziness;
feeling like you might pass out; or
severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
Less serious side effects of naloxone / pentazocine may include:
feeling restless or irritable;
dry mouth, nausea, vomiting, loss of appetite;
tremor, chills, sweating;
flushing (warmth, redness, or tingly feeling);
sleep problems (insomnia), strange dreams;
blurred vision; or
ringing in your ears.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to naloxone / pentazocine: oral tablet
A 45-year-old male narcotic addict and alcoholic with hepatitis and undiscovered cardiomyopathy was given 0.8 mg of naloxone intravenously over a 2 minute period and developed ventricular fibrillation. The patient required naloxone once more for this episode and again developed ventricular fibrillation. A second opioid overdose in the same patient was treated with an initial dose of 0.4 mg intravenously, followed by 0.4 mg intravenously, then intramuscularly. Each time the patient developed ventricular fibrillation responsive to cardioversion and/or lidocaine.
Severe hypertension (mean arterial pressure rising from a baseline of 107 mmHg to 147 mmHg in about 2 to 3 hours) has been reported in an essential hypertension patient given an initial 8 mg dose of naloxone intravenously, followed by an infusion of 0.13 mg/min over the next 2.5 hours. When the naloxone was discontinued the blood pressure quickly returned to normal.
Mild hypotension and one case of moderate hypertension were observed in patients receiving a bolus dose of 4 mg/kg of naloxone followed by 2 mg/kg/hour for 24 hours. One study reported that the newborn infants of mothers who have received naloxone near term may experience tachycardia.
Cardiovascular side effects with the use of naloxone have included hypotension, hypertension, atrial and ventricular tachycardia, ventricular fibrillation, left ventricular failure and cardiac arrest (mostly in postoperative patients, many of whom had cardiovascular disease).
Cardiovascular side effects including a decrease in blood pressure and tachycardia have been reported infrequently with the use of pentazocine.
Withdrawal syndromes from the use of naloxone may be precipitated by as little as 0.05 to 0.2 mg intravenously in patients taking 24 mg per day of methadone.
Other side effect including withdrawal in patients receiving opioids have been precipitated by naloxone. Withdrawal is characterized by nausea, vomiting, sweating, lacrimation, rhinorrhea, cramping, insomnia, chills/hot flashes, piloerection, tachycardia, anxiety, restlessness, irritability, tremulousness, hypertension, seizures, and cardiac arrest. Similar symptoms have been noted in patients with pruritus of cholestasis who were not receiving opiates.
Other side effects including tinnitus have been reported with the use of pentazocine.
Three cases, treated with numerous drugs, developed clinical evidence of pulmonary edema shortly after intravenous administration of naloxone (0.3 to 1.6 mg).
Respiratory side effects including pulmonary edema have been uncommon from the use of naloxone.
Respiratory side effects including respiratory depression have rarely been reported with the use of pentazocine.
A 51-year-old male was given 0.8 mg of naloxone for obtundation. Within 30 seconds of administration a grand mal seizure occurred. The patient had Pseudomonas sepsis with negative CSF cultures.
Nervous system side effects including seizures and paresthesias have been reported at both standard and high dosages of naloxone. Seizures have been reported in 5% of patients receiving a bolus of 4 mg/kg followed by 2 mg/kg/h for 24 hours. Agitation has been noted in 3%, tremors in 3%, and headache in 5%. Rarely, agitation, tremors, headache, alteration in mood and cognition, mental discomfort, sleepiness, and confusion have been reported at high dosages. Lethargy has been reported in manic and control patients. Naloxone administration may worsen obsessive compulsive behavior.
Nervous system side effects including sweating, dizziness, lightheadedness, hallucinations, sedation, euphoria, headache, confusion, and disorientation have been reported with the use of pentazocine. Weakness, flushing, disturbed dreams, insomnia, and syncope have been reported infrequently. Tremor, chills, paresthesia, irritability, and excitement have been reported rarely.
Nausea and/or vomiting occurred in 32% of patients in one study on naloxone who received a bolus of 4 mg/kg followed by 2 mg/kg/h for 24 hours.
Gastrointestinal side effects of nausea and vomiting have been reported in patients receiving high dose naloxone therapy.
Gastrointestinal side effects including nausea and vomiting have been reported with the use of pentazocine. Constipation has been reported infrequently. Abdominal distress, anorexia, and diarrhea have been reported rarely.
Genitourinary side effects including an increase in urinary urgency have rarely been reported with the use of naloxone. The drug may also have a mild diuretic effect.
Genitourinary side effects including urinary retention have rarely been reported with the use of pentazocine.
A 75-year-old was treated with naloxone for senile dementia. A dosage of 0.8 mg in 25 mL of normal saline was given as an infusion over 10 minutes. The treatment was given 6 times, each time the patient experienced urinary urgency (at least 5 small volume urinations over 2 hours).
Depression of the white blood cell count is usually reversible.
Hematologic side effects including depression of the white blood cell count (especially granulocytes) and moderate transient eosinophilia have been reported with the use of pentazocine.
Hypersensitivity reactions including rash have been reported infrequently. Urticaria and edema of the face have been reported rarely with the use of pentazocine. One instance of an apparent anaphylactic reaction has been reported.
Dermatologic side effects including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported rarely with the use of pentazocine.
Ocular side effects including visual blurring and focusing difficulty have been reported infrequently with the use of pentazocine.
Psychiatric side effects including depression have been reported infrequently with the use of pentazocine.
More Talwin Nx resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.